GSK’s New Phase 3 Endometrial Cancer Trial Moves Forward, Putting Oncology Pipeline in Focus

GlaxoSmithKline (GSK) announced an update on their ongoing clinical study.

The Phase 3 BEHOLD-Endometrial01 study, formally titled “A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer,” aims to see if GSK5733584 can control the disease better than standard chemotherapy and with acceptable safety. The focus is on women with recurrent endometrial cancer, a setting where new options are limited and clinical need remains high.

The trial tests GSK5733584, an experimental cancer drug from GlaxoSmithKline, against current standard treatments Paclitaxel and Doxorubicin. The goal is to show that GSK5733584 can improve outcomes while keeping side effects manageable compared with existing chemotherapy.

The study uses a randomized design, so participants are assigned by chance to receive either GSK5733584 or standard chemotherapy. It is open label for patients and doctors, but an independent reviewer who measures the main results is blinded, which helps reduce bias while keeping the design practical in real-world cancer care.

The study was first submitted on 12 Dec 2025 and is currently listed as not yet recruiting, meaning sites are preparing to enroll patients. The most recent update to the record was posted on 10 Mar 2026, showing that the protocol and planning details are active and moving forward even though primary and final completion dates are not yet set.

For investors, this update signals that GSK is pushing deeper into gynecologic oncology, a segment with growing demand as survival improves and recurrence remains common. Positive Phase 3 data in recurrent endometrial cancer could support a new revenue stream for GSK, influence long-term growth expectations, and pressure rivals focused on women’s cancers.

The study also highlights the role of key cooperative groups such as ENGOT and the GOG Foundation, which can speed enrollment and raise trial visibility among specialists. Strong engagement from these networks may improve confidence that the trial will recruit efficiently, an important factor for timelines that can move GSK’s share price when key data readouts approach.

Sentiment in oncology remains selective, and investors will likely wait for clear efficacy and safety signals before re-rating GSK’s valuation on this asset. Still, adding a late-stage program in a hard-to-treat cancer can support the pipeline narrative and may help offset concerns about patent cliffs and competition from large peers in U.S. and European cancer markets.

With the BEHOLD-Endometrial01 study now updated and moving toward enrollment, the program remains an ongoing watch item for healthcare investors, and further operational and clinical details are available on the ClinicalTrials portal.

To learn more about GSK’s potential, visit the GlaxoSmithKline drug pipeline page.